Pharmacogenomics studies how medicine interacts with inherited genes. This includes how inherited genes affect the way medications work for each person. Genetic differences mean that a drug can be safe for 1 person but harmful for another. One person may experience severe side effects from it. Another may not, even when given a similar dose.

Standard genetic testing. Standard genetic testing searches for specific genes. For example, BRCA1 and BRCA2 genes. These genes are linked with a higher risk of breast and ovarian cancer. Standard genetic test results may prompt preventive steps.

Preventive steps include:

Pharmacogenomics. Pharmacogenomics is a kind of genetic testing. It looks for small variations within genes. These variations may affect whether genes activate or deactivate specific drugs. Test results help the doctor choose the safest and most effective drug and dose.

Pharmacogenomics is constantly changing. Researchers continue to identify gene variations that affect how a drug works. As personalized medicine grows, testing for gene variations may become more common.

Drug activation. Many drugs that treat cancer need activation to work. Activation is the process of turning on. Proteins called enzymes speed up chemical reactions in the body. This activates a drug so that it can do its job.

Each person inherits variations in enzymes. The variations affect how fast a drug changes into its active form. For example, some people break down drugs slowly. This means standard doses of treatment may not work as well.

Drug deactivation. Drugs also need deactivation to limit the drugs exposure to healthy tissues. Deactivation is the process of turning off.

Some people may have slower enzymes. As a result, high levels of the drug may remain in their bodies for a long time. This means that they may have more side effects from the drug.

Besides pharmacogenomics, other factors may influence a persons reaction to a drug:

Here are some of the benefits of pharmacogenomics:

It may improve patient safety. Severe drug reactions cause more than an estimated 120,000 hospitalizations each year. Pharmacogenomics may prevent these by identifying patients at risk.

It may improve health care costs and efficiency. Pharmacogenomics may help find appropriate medications and doses more quickly.

Here are some challenges in the development and practical use of pharmacogenomics:

It is expensive, particularly if insurance does not cover the costs.

Access to certain tests may be limited in some places.

Privacy issues remain, despite federal antidiscrimination laws. These laws prohibit discrimination based on genetic information.

Here are some examples of pharmacogenomic testing in cancer care:

Colorectal cancer. Irinotecan (Camptosar) is a type of chemotherapy. Doctors commonly use it to treat colon cancer. In some people, genetic variations cause a shortage of the UGT1A1 enzyme. This enzyme is responsible for metabolizing irinotecan. Metabolism is the chemical reaction that helps the body process the drug.

With a UGT1A1 shortage, higher levels of irinotecan remain in the body. This may lead to severe and potentially life-threatening side effects. The risk is greater with higher doses of the drug.

Doctors may use a pharmacogenomic test called the UGT1A1 test. It shows which people have this genetic variation. Then, the doctor may prescribe a lower dose of irinotecan. Often, the lower dose is just as effective for these people.

Acute lymphoblastic leukemia (ALL). Doctors use pharmacogenomic testing for children with ALL. About 10% of people have genetic variations in an enzyme called thiopurine methyltransferase (TPMT). TPMT is responsible for metabolizing chemotherapy for ALL.

Children with lower TPMT levels receive lower chemotherapy doses. This prevents severe side effects.

Other cancer types. Fluorouracil (5-FU) is a type of chemotherapy. Its used to treat several types of cancer including colorectal, breast, stomach, and pancreatic cancers.

A genetic variation in some people causes lower levels of the enzyme called dihydropyrimidine dehydrogenase (DPD). DPD helps the body metabolize fluorouracil.

Doctors may use a pharmacogenomic test to find this variation. If found, a lower fluorouracil dose helps prevent serious side effects.

Talk with your health care team about your treatment options and consider asking the questions below:

What are my treatment options?

Which treatment or combination of treatments do you recommend? Why?

Do these treatments work differently in different people? If so, are there tests to find these differences?

What are the possible side effects of this treatment?

Could my genetic makeup affect my bodys response to treatment?

Is there a way to predict how my body will respond to this drug? To predict whether I might experience severe side effects?

What are my options if the cancer does not respond to the drug? Or if I experience severe side effects?

Whom should I call with questions or problems?

Genetics

National Institutes of Health: Frequently Asked Questions About Pharmacogenomics

Continue reading here:
Understanding Pharmacogenomics | Cancer.Net

General Description, Overview, and Opportunities

Pharmacogenomics has increasingly become an area of interest to clinicians because of the potential to tailor pharmacotherapy based on genetic variations in patients. Pharmacogenomics is one of the key aspects of personalized medicine, focusing on how an individual's DNA affects the way they respond to medications. All individuals have different genetic make-up so they respond differently to the same medication. Based on this insight, pharmacogenomics allows customized treatment for a wide range of health problems including; cardiovascular disease, Alzheimer's disease, cancer, HIV/AIDS, and asthma. Often, drug choice and dosage require experimentation (trial and error) in order to find the best treatment option. With pharmacogenomics testing, the need for this experimentation is decreased. As a result, the process becomes faster and more cost-effective and the possibility of adverse events caused by the wrong drug choice or dosage is significantly reduced.

One avenue for implementing pharmacogenomic is through medication therapy management (MTM), where pharmacists assess and evaluate a patient's complete medication therapy regimen. By gathering key pieces of information, e.g. which medications and supplements a patient is currently taking, pharmacists can assess current treatment and suggest alternative therapies.

As medication experts and POC service providers, pharmacists can educate physicians and patients and perform the actual sample collection to be utilized for genetic testing. The broad application of pharmacogenomics to personalized medicine will improve patient outcomes and lower healthcare costs.

Test Features

Pharmacies require a lab partner to provide clinically relevant data and interpret results for physicians. Most tests screens all well-established pharmacogenomics genes in a single, cost-effective test. Results are delivered quickly via intuitive, clinically relevant, medically actionable report. The data provides lifetime utility of data, thereby decreasing the need for future testing.

Community pharmacists routinely perform point of care services and can assist patients by:

Performing a buccal swab in minutes

Send the collected DNA to the lab

Interpret results and discuss with physicians

Contact the patient to explain the results and any changes in therapy

Companies

Pharmacist Resources and Training

Read the original:
Pharmacogenomics - NCPA

AmpliSeq On-Demand Panels: Coming up with different design combinations for a panel requires time and effort. And you guys are doing all the work I like the idea of ordering only the genes that I see more

- Dr. William G. Kearns, PhD Founder & Director AdvaGenix Rockville, US

AmpliSeq On-Demand Panels: Coming up with different design combinations for a panel requires time and effort. And you guys are doing all the work I like the idea of ordering only the genes that I want, and being able to roll with it.

AmpliSeq On-Demand Panels: the majority of the projects we provide service for has only a few samples...it is good to have a small pack size...we have been limited because of the cost...this may see more

- Dr. Adam Ameur Department of Immunology, Genetics and Pathology Uppsala University

AmpliSeq On-Demand Panels: the majority of the projects we provide service for has only a few samples...it is good to have a small pack size...we have been limited because of the cost...this may possibly open up other studies...looking at larger genes with fewer samples Our results look very promising with even coverage across all samples and 100% of known variants detected"

AmpliSeq On-Demand Panels: "..you can kind of cherry pick genes of interest and design your own panel...so I like it"

- Dr. Michal Mikula Department of Genetics Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Warsaw, Poland

AmpliSeq On-Demand Panels: "..you can kind of cherry pick genes of interest and design your own panel...so I like it"

AmpliSeq On-Demand Panels: Cost was a limiting factor for panels with a large number of amplicons. For labs who need to change their gene content frequently, the lower price for oligos is really see more

- Dr. Pan Zhang, PhD, MD Director, Sequencing and Microarray Center Coriell Institute for Medical Research

AmpliSeq On-Demand Panels: Cost was a limiting factor for panels with a large number of amplicons. For labs who need to change their gene content frequently, the lower price for oligos is really great

See the original post:
Ion AmpliSeq Designer

Akonni'splatform delivers accurate, multiplexed analysis in a low-cost format, offering a valuable solution for healthcare applications such as disease prediction and prevention, early diagnosis, identification of drug resistance, and treatment monitoring.

SANTA CLARA, California, Aug. 15, 2017 /PRNewswire/ -- Based on its recent analysis of microarrays in molecular diagnostics (MDx), Frost & Sullivan recognizes Akonni Biosystems, Inc. with the 2017 North America Frost & Sullivan Award for New Product Innovation. Akonni's integrated MDx system, TruDiagnosis, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis is powered by TruArray, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time. Frost & Sullivan believes that Akonni is properly positioned to serve the precision medicine revolution.

Click here for the full multimedia experience of this release - http://bit.ly/2wJbPPQ

"TruDiagnosis offers rapid, reliable multiplexed analysis at a lower overall cost per array," reports Frost & Sullivan Senior Research Analyst Sanchari Chatterjee Maity. "The company modified this platform by replacing the traditional glass substrate with a cost-effective plastic film substrate for printing arrays without requiring functionalized coatings. Akonni also enhanced the manufacturing process for reel-to-reel manufacturing of arrays on film to generate greater cost efficiencies."

TruDiagnosis consists of Akonni's proprietary TruDx Imagers, TruArray Assays, and TruTip sample prep kits and includes nucleic acid extraction as well as fully-automated gridding and data analysis software for patient reporting. The platform serves a range of applications such as pharmacogenomics, chronic human diseases (cancer), infectious diseases, extensive drug-resistant tuberculosis, upper respiratory infections, viral encephalitis, and hospital-acquired infections.

At the heart of the platform is the TruArray 3D gel-drop technology, which delivers efficient immobilization capacity due to the innovative spacing design of the immobilized molecules throughout the volume of the gel drop. This design boasts high hybridization efficiency, which helps achieve specific hybridization to obtain incredibly accurate data. The low-density microarrays can carry between 5 and 400 3D gel-drops per array.

TruDiagnosis has garnered considerable praise for its easy mode of operation and accurate results. The testing procedure involves dropping a few microliters of the DNA sample onto a microfluidic test slide the size of a stick of chewing gum. The sample then flows over an array of the 3D gel-drops with probes that test for the targets of interest; for example, Akonni's multi-drug resistant mycobacterium TB (MDR-TB) test includes six tuberculosis (TB) genes and 88 strain-specific mutations. Akonni facilitates workflows by combining conventional target amplification, fragmentation, and labeling processes into a single microfluidic chamber. Additionally, the integrated, self-contained design of the microfluidic device alleviates the risk of amplicon contamination following polymerase chain reaction (PCR) amplification. Once the assay is finished, the test is inserted in the TruDx reader, which detects and indicates a genetic match. This operational method takes significantly less computation time than other diagnostic microarrays.

Pre-clinical studies demonstrate the superiority of TruDiagnosis' clinical viability over traditional multiplexed platforms. "Akonni has won several projects from leading private as well as government entities in North America and Asia-Pacific due to the versatility of its diagnostic products," noted Chatterjee Maity. "Overall, it enjoys a solid market presence and is well positioned for higher growth due to its effective products, customer-friendly approach, strategic execution of business prospects, and cost effectiveness."

Each year, Frost & Sullivan presents this award to a company that develops an innovative product element by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it affords customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Akonni Biosystems, Inc.

Akonni Biosystems was founded in 2003 and has been issued 21 US and 36 International patents primarily covering sample preparation, microfluidic devices, bioinstrumentation, and integrated systems. Product development has been supported by a series of government grants and contracts from NIH, CDC, DOE, DOD, NIJ, and NSF. The company significantly advanced the original technology by improving the system's capabilities from sample preparation to test result. Commercial products in Akonni's near-term pipeline include rapid sample preparation technologies for nucleic acid extraction and multiplex panel assays for detecting clinically relevant genotypes for pharmacogenomics, human chronic diseases, and genotypes for infectious diseases such as multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), upper respiratory infections, viral encephalitis, and hospital-acquired infections (MRSA).

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Ana ArriagaP: 210.247.3823F: 210.348.1003E: rel="nofollow">ana.arriaga@frost.com

Read more:
Frost & Sullivan Awards Akonni Biosystems for its Groundbreaking TruDiagnosis Molecular Diagnostics Platform - Markets Insider

(April 14, 2017)

Dear ESPT member,First of all, I would like to thank you for your continued support of the European Society for Pharmacogenomics and Personalized Therapy (ESPT). With this email, I would like to update you on the activities of ESPT, and inform you about interactions with you as members regarding the direction and strategies of our society. The ESPT Board has been strengthened in October 2016 by Dr .Sanja Stankovic (Belgrade, Serbia) and Csilla Sipeky (Turku, Finland). Sanja took over the general secretariat from Janja Marc, whereas Ingolf Cascorbi (Kiel, Germany) took over the treasurer position from Sofia Siest. Janja Marc has taken over the Educational Division activities from Vangelis Manolopoulos. The Division Scientific Research and Clinical Implementation will be split in two individual Divisions, with Ron van Schaik (NL) leading the Clinical Implementation Division, collaborating with the European Pharmacogenetic Implementation Consortium (www.eu-pic.net) whereas Marc Ansari (CH) will chair the Research Division. ESPT has now a new Executive office, located in Milan, giving us the opportunity to professionalize our society as well as having a physical headquarter for meetings. Address: ESPT Executive Office, Via Carlo Farini 81, 20159 Milano, ItalyThe ESPT society itself will maintain its main registration in France. As ESPT, have been active in 2017 in setting up and/or extending collaborations with the Finnish National Society for Pharmacogenetics , the Turkish Society for Pharmacogenetics and the Serbian Society for Pharmacogenetics. ESPT has been present at the CPIC meeting in Washington DC (March 15), the ASCPT Annual meeting (Washington DC, March 16-18) and the UK Pharmacogenomics & Stratified Medicine Network Meeting (March 23) in London, UK.The preparations for the ESPT Annual Meeting 2017 (Oct 4-7) in Catania, Sicily, are in full progress. At this moment, 90% of the invited speakers have confirmed. It is expected that registration will start in 6 weeks. Already, we received a lot of positive reactions to this meeting. Also, the ESPT General Assembly will take place in Catania. More information will follow shortly. In the next months, ESPT will be present at the QLAC meeting in Belgrade (April 19-21), the Global Genomic Medicine Alliance meeting (Athens, April 27-29) , the WPA Interzonal congress in Vilnius, Lithuania (May 4-6), the Pharmaceutical World Congress in Stockholm (May 21-24) and the Human Genome Variation Society meeting (Copenhagen, May 26). Hope this update will give you more insight in the developments ongoing!Kindest regards,

The Society

Continued here:
Home [www.esptnet.eu]

Cytochrome P450 2C9 (abbreviated CYP2C9) is an enzyme that in humans is encoded by the CYP2C9 gene.[5][6]

CYP2C9 is an important cytochrome P450 enzyme with a major role in the oxidation of both xenobiotic and endogenous compounds. CYP2C9 makes up about 18% of the cytochrome P450 protein in liver microsomes (data only for antifungal). Some 100 therapeutic drugs are metabolized by CYP2C9, including drugs with a narrow therapeutic index such as warfarin and phenytoin and other routinely prescribed drugs such as acenocoumarol, tolbutamide, losartan, glipizide, and some nonsteroidal anti-inflammatory drugs. By contrast, the known extrahepatic CYP2C9 often metabolizes important endogenous compound such as serotonin and, owing to its epoxygenase activity, various polyunsaturated fatty acids, converting these fatty acids to a wide range of biological active products.[7][8]

In particular, CYP2C9 metabolizes arachidonic acid to the following eicosatrienoic acid epoxide (termed EETs) stereoisomer sets: 5R,6S-epoxy-8Z,11Z,14Z-eicosatetrienoic and 5S,6R-epoxy-8Z,11Z,14Z-eicosatetrienoic acids; 11R,12S-epoxy-8Z,11Z,14Z-eicosatetrienoic and 11S,12R-epoxy-5Z,8Z,14Z-eicosatetrienoic acids; and 14R,15S-epoxy-5Z,8Z,11Z-eicosatetrainoic and 14S,15R-epoxy-5Z,8Z,11Z-eicosatetrainoic acids. It likewise metablizes docosahexaenoic acid to epoxydocosapentaenoic acids (EDPs; primarily 19,20-epoxy-eicosapentaenoic acid isomers [i.e. 10,11-EDPs]) and eicosapentaenoic acid to epoxyeicosatetraenoic acids (EEQs, primarily 17,18-EEQ and 14,15-EEQ isomers).[9] Animal model and a limited number of human studies implicate these epoxides in reducing hypertension; protecting against the Myocardial infarction and other insults to the heart; promoting the growth and metastasis of certain cancers; inhibiting inflammation; stimulating blood vessel formation; and possessing a variety of actions on neural tissues including modulating Neurohormone release and blocking pain perception (see epoxyeicosatrienoic acid and epoxygenase pages).[8]

In vitro studies on human and animal cells and tissues and in vivo animal model studies indicate that certain EDPs and EEQs (16,17-EDPs, 19,20-EDPs, 17,18-EEQs have been most often examined) have actions which often oppose those of another product of CYP450 enzymes (e.g. CYP4A1, CYP4A11, CYP4F2, CYP4F3A, and CYP4F3B) viz., 20-Hydroxyeicosatetraenoic acid (20-HETE), principally in the areas of blood pressure regulation, blood vessel thrombosis, and cancer growth (see 20-Hydroxyeicosatetraenoic acid, Epoxyeicosatetraenoic acid, and Epoxydocosapentaenoic acid sections on activities and clinical significance). Such studies also indicate that the EPAs and EEQs are: 1) more potent than EETs in decreasing hypertension and pain perception; 2) more potent than or equal in potency to the EETs in suppressing inflammation; and 3) act oppositely from the EETs in that they inhibit angiogenesis, endothelial cell migration, endothelial cell proliferation, and the growth and metastasis of human breast and prostate cancer cell lines whereas EETs have stimulatory effects in each of these systems.[10][11][12][13] Consumption of omega-3 fatty acid-rich diets dramatically raises the serum and tissue levels of EDPs and EEQs in animals as well as humans and in humans are by far the most prominent change in the profile of PUFA metabolites caused by dietary omega-3 fatty acids.[10][13][14]

CYP2C9 may also metabolize linoleic acid to the potentially very toxic products, vernolic acid (also termed leukotoxin) and coronaric acid (also termed isoleukotoxin); these linoleic acid epoxides cause multiple organ failure and acute respiratory distress in animal models and may contribute to these syndromes in humans.[8]

9-tetrahydrocannabinol (9-THC), cannabidiol (CBD) and cannabinol (CBN), the three major constituents in cannabis, are found to be direct inhibitors for CYP2C9.[15]

Genetic polymorphism exists for CYP2C9 expression because the CYP2C9 gene is highly polymorphic. More than 50 single nucleotide polymorphisms (SNPs) have been described in the regulatory and coding regions of the CYP2C9 gene;[16] some of them are associated with reduced enzyme activity compared with wild type in vitro.[citation needed]

Multiple in vivo studies also show that several mutant CYP2C9 genotypes are associated with significant reduction of in metabolism and daily dose requirements of selected CYP2C9 substrate. In fact, adverse drug reactions (ADRs) often result from unanticipated changes in CYP2C9 enzyme activity secondary to genetic polymorphisms. Especially for CYP2C9 substrates such as warfarin and phenytoin, diminished metabolic capacity because of genetic polymorphisms or drug-drug interactions can lead to toxicity at normal therapeutic doses.[17][18]

Allele frequencies(%) of CYP2C9 polymorphism

Most inhibitors of CYP2C9 are competitive inhibitors. Noncompetitive inhibitors of CYP2C9 include nifedipine,[19][20] phenethyl isothiocyanate,[21] medroxyprogesterone acetate[22] and 6-hydroxyflavone. It was indicated that the noncompetitive binding site of 6-hydroxyflavone is the reported allosteric binding site of the CYP2C9 enzyme.[23]

Following is a table of selected substrates, inducers and inhibitors of CYP2C9. Where classes of agents are listed, there may be exceptions within the class.

Inhibitors of CYP2C9 can be classified by their potency, such as:

CYP2C9 attacks various long-chain polyunsaturated fatty acids at their double (i.e. alkene) bonds to form epoxide products that act as signaling molecules. It along with CYP2C8, CYP2C19, CYP2J2, and possibly CYP2S1 are the principle enzymes which metabolizes 1) arachidonic acid to various epoxyeicosatrienoic acids (also termed EETs); 2) linoleic acid to 9,10-epoxy octadecaenoic acids (also termed vernolic acid, linoleic acid 9:10-oxide, or leukotoxin) and 12,13-epoxy-octadecaenoic (also termed coronaric acid, linoleic acid 12,13-oxide, or isoleukotoxin); 3) docosohexaenoic acid to various epoxydocosapentaenoic acids (also termed EDPs); and 4) eicosapentaenoic acid to various epoxyeicosatetraenoic acids (also termed EEQs).[8] Animal model studies implicate these epoxides in regulating: hypertension, Myocardial infarction and other insults to the heart, the growth of various cancers, inflammation, blood vessel formation, and pain perception; limited studies suggest but have not proven that these epoxides may function similarly in humans (see epoxyeicosatrienoic acid and epoxygenase pages).[8] Since the consumption of omega-3 fatty acid-rich diets dramatically raises the serum and tissue levels of the EDP and EEQ metabolites of the omega-3 fatty acid, i.e. docosahexaenoic and eicosapentaenoic acids, in animals and humans and in humans is the most prominent change in the profile of PUFA metabolites caused by dietary omega-3 fatty acids, EPA and EEQs may be responsible for at least some of the beneficial effects ascribed to dietary omega-3 fatty acids.[36][37][38]

PDB gallery

1og2: STRUCTURE OF HUMAN CYTOCHROME P450 CYP2C9

1og5: STRUCTURE OF HUMAN CYTOCHROME P450 CYP2C9

1r9o: Crystal Structure of P4502C9 with Flurbiprofen bound

Go here to see the original:
CYP2C9 - Wikipedia

This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker.

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century.

Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics.

Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in use of pharmacogenetics, pharmacogenomics and pharmacoproteomics for development of personalized medicine.

Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed.

Biomarker markets are estimated from 2016 to 2026 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.

A large number of companies with varying technical backgrounds are involved in biomarkers and 304 of these are profiled in part 2 of the report with classification into various categories.These also include major pharmaceutical companies. There is tabulation of 467 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies. The report is supplemented by 1,200 references, 77 tables and 20 figures

Key Topics Covered:

Part 1: Technologies & Markets

Executive Summary

1. Introduction

2. Technologies for Discovery of Biomarkers

3. Biomarkers and Molecular Diagnostics

4. Biomarkers for Drug Discovery & Development

5. Role of Biomarkers in Healthcare

6. Biomarkers of Cancer

7. Biomarkers of Disorders of the Nervous System

8. Biomarkers of Cardiovascular Disorders

9. Biomarkers & Personalized Medicine

10. Biomarkers and Regulatory issues

11. Markets for Biomarkers

12. References

Part II: Companies

13. Companies

For more information about this report visit https://www.researchandmarkets.com/research/4nrrhw/biomarkers

Source: Jain PharmaBiotech

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biomarkers-technologies-markets-and-companies-projections-report-2017-300483376.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the rest here:
Global Biomarkers Technologies, Markets and Companies Projections Report 2017 - PR Newswire (press release)

Theme: Advanced Approaches in Genomics and Pharmacogenomics

It gives us immense pleasure to announce the conference that is 10th International Conference on Genomics & Pharmacogenomics.

Genomics 2018 will provide a perfect platform to all the Scientists, Researchers, Students and Business Delegates to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Genomics 2018 Genomics is an area within genetics that concerns the sequencing and analysis of an organisms genome. Genomics also involves the study of intragenomic processes such as epistasis, heterosis and pleiotropy as well as the interactions between loci and alleles within the genome. The fields of molecular biology and genetics are mainly concerned with the study of the role and function of single genes, a major topic in todays biomedical research. By contrast, genomics does not involve single gene research unless the purpose is to understand a single genes effects in context of the entire genome

Conference Highlights: Cancer Genomics, Functional Genomics, Next Generation Sequencing, Biomarkers & Molecular Markers, Pharmacogenomics & Personalized Medicine, Clinical Genomics, Micro RNAm, RNA Analysis, Bioinformatics in Genomics, Comparative Genomics, Plant Genomics, Genome Engineering, Microbial Genomics, Future trends in Genomics, Genome Medicine, and Genomics Market

Link of the conference: http://genomics.conferenceseries.com/

Conference Mail ID: genomics@conferenceseries.net, genomics@geneticconferences.com

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Visit link:
10th International Conference on Genomics and Pharmacogenomics - Technology Networks

Sessions and Tracks

The 6thEuropeanConference on Predictive Preventive and Personalized Medicine & Molecular Diagnostics will be held on September 14-15, 2017 at Edinburgh, Scotland will be organized around the themeUnleashing the novel approaches in advancing Personalized Medicinewhichcomprises 23 Sessions/Tracksto outline the theme of the conference organized by conferenceseries LLCConferences. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Track 1: Molecular Diagnostics in Personalized Medicine

In personalized medicine molecular diagnostics is used for analysing of biological markers and also analysing by applying molecular biology to medical testing .This technique is used to diagnose and monitor disease,detect risk in individual patients .DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule .SNP genotyping is the measurement of genetic variations of single nucleotide polymorphism (SNPs) . which is the measurement of more general genetic variation.Gene expression profiling is used for the measurement of the activity of thousands of genes at once.

Relevant conferences:

InternationalConference on Medical Imaging & Diagnosis,May 09 - 10, 2016 ,Chicago,US. InternationalCancer Study & Therapy Conference, 46 April 2016 ,Baltimore,United States.Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.

Related Associations:

Alzheimers and Dementia Testing for Earlier Diagnosis

Association for Molecular Pathology Establishes New Standard for Clinical Utility of Molecular Diagnostics

British In Vitro Diagnostics Association (BIVDA)

California Life Sciences Association- Molecular Diagnostics

American Board of Clinical Chemistry

Molecular Diagnostics Laboratory

Association for Molecular pathology

Track2: Biomarkers Personalized Medicine

In personalized medicine biomarkers and biological marker generally refers to a measurableindicator of some biological state or condition. This word refer to a substance the presence of which indicates the existence of aliving organism. Biochemical biomarkers are often used inclinical trials, Biomarkers used for personalized medicine are typically categorized as either prognostic or predictive .In , a biomarkersis a molecule that allows the detection and isolation of a particular cell type. A biomarker indicates a change in state of a protein that correlates with the risk or progression of a disease . Biomarkers are useful in a number of ways, including measuring the progress of disease. Biomarkers also used in early diagnosis, disease prevention, drug target identification, drug response etc.

Relevant conferences :

International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US. .International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome ,Italy.

Related Associations:

ALS research Association

European society of cardiology

American Association of Pharmaceutical Scientists

American Board of Clinical Chemistry

Track3: Pharmacogenetic in Personalized Medicine

In personalized medicine pharmacogenetics is the study of inherited genetic differences in drug metabolic pathways which can affect the drug responses, like therapeutic effect as well as adverse effect. Inter- and intra-individual variation in gene expression and its function.In oncology, pharmacogenetics refers to germline mutations and pharmacogenomics is study the somatic mutations in tumoral DNA leading to alteration in drug response

Relevant conferences :

Nanomaterials and Nanobiotechnolog Conference April 21-23, 2016 Dubai, UAE. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy. European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain. World congress on Translation genomics,28 feb - 2 march, 2016,houstan, USA. Personalised Medicine Conference ,1-2 June,2016, Brussels, Belgium.

Related Associations:

European Society of Pharmacogenomics and Personalized Medicine

American Society of Human Genetics

Hungarian Society of Personalized Medicine

American Society for Investigative Pathology

Association for Molecular Pathology

Track4: Pharmacogenomics in Personalized Medicine

Pharmacogenomics is the study of the role of genetics in drug response. It deals with the influence of acquired and inheritedgeneticvariation on drug response, drug absorption distribution, metabolism, and elimination ,as well as drug receptor target effects . Pharmacogenomics is often used interchangeably with pharmacogenetics.Pharmacogenomics is used for the detection of the individual genetic variation with drug responses pharmacogenetics focuses on single drug-gene interactions, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response

Relevant conferences :

International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome ,Italy.

Related Associations:

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

Track5: Pharmacoproteomics in Personalized Medicine

The proteome is the entire set of proteins it is expressed by genome , cell, tissue, or organism at a certain time. More specifically, it is a combined of proteins and genomes . Proteomics is the study of the proteome. A cellular proteome is the collection of proteins present in a particular cell type and it exposure to harmone stimulation . It can also be useful to consider an organisms complete proteome, which can be conceptualized as the complete set of proteins from all of the various cellular proteomes. Proteome used to refer to the collection of proteins in certain sub-cellular biological systems.

Relevant conferences:

International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy .European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain .World congress on Translation genomics , 28feb - 2 march ,2016, houstan,USA . Personalised Medicine Conference ,1-2 June,2016, Brussels, Belgium. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States.

Related Associations:

International precision medicine Associates

International Society of Personalized Medicine

British Society for Proteome Research

European Proteomics Association

Swiss Proteomics Society

Japan Society for clinical Proteomics

Track6: Metabolomics in Personalized Medicine

Metabolomics is defined as the chemical processes involving of metabolites. Metabolomics is the study of the unique chemical fingerprints. The metabolome refers to the collection of all metabolites in a biological cell, tissue, organ or organism. mRNA gene expression data and proteomic analyses reveals the set of gene products in the cell. One of the challenges of system biology and functional genomics is to integrate proteomic ,transcriptomic, and metabolomic information to provide a cellular biology.

Relevant conferences :

Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Metabolomics Society

The Metabolomics Standards Initiative (MSI)

Metabolomics for a Low Carbon Society (METABOLOMICS)

Swiss Metabolomics Society

Metabolomics Research Group (MRG)

Track7: Personalized in Health Care

Personalized medicineis aMedical Practice that separates patients into different groups with medical decisions, practices, interventions and products being tailored to the individual patient based on their predicted response or risk of disease. The words of personalized medicine,precision medicine,stratified medicineand P4 medicine are used interchangeably .

Relevant conferences :

International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE . International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore , United States. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016,Snowbird,United States . International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore , United States. International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy. European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain.

Related Associations:

American Health Care Association

Florida Health Care Association

OHCA Oregon Health Care Association

Texas Health care Association

Washington Health Care Association

Track8: Non- genomics Personalized Medicine

Epigenomics is a set of epigenetic modifications on the genetic material of a cell is called as the epigenome. Epigenetics are reversible modifications on a cells DNA that affect the gene expression without altering the DNA sequence. Epigenetic modifications are important role in the gene expression and regulation, that are involved in the numerous cellular processes such as tumorigenesis.

Relevant conferences:

Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird,United States.International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Genome Wide Association Studies (GWAS)

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

German society of Human Genetics

Track9: Personalized Biological Therapies

Biological therapy refers to the use of medication , specifically target an immune or genetic mediator of disease. Even for diseases of unknown cause of molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. which are mainly cytokines , are directly involved in the immune system .Biological therapy used for the management of cancer , autoimmune disease, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

Relevant conferences :

International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Human Biology Association

American Biological Safety Association

Society for Conversation Biology

Association for Tropical Biology

American Institute of Biological Sciences

American Society for Microbiology

Track10: Personalized Management of Cancer Therapy

More here:
Updated Scientific Program | Euro Personalized Medicine ...

Therapeutic applications such as cardiology, oncology, neurological disorder, and pain management will keep the global Pharmacogenomics Market in good stead in the near future.

Rising usage of Pharmacogenomics in drug discovery processes, prevalence of various infectious as well as non-infectious diseases, growing demand for personalized drugs, and increasing awareness regarding the benefits of customized medication are some of the key factors augmenting the demand in the global pharmacogenomics market. The concept of pharmacogenomics has the ability to serve subpopulations on the basis of susceptibility to particular disease, as individual response of a drug depends on genetic composition. Rise in investment in research and development and advancement in technology pharmacogenomics engineering to create in vivo environment are some of the other factors favoring the global pharmacogenomics market. Some of the drugs used for pharmacogenomics tests are thiopurines, warfarin, clopidogrel, abacavir, irinotecan, phenytoin, and carbamazepine. These tests are useful for diseases such as autoimmune or childhood leukemia, excessive clotting disorder, cancer, cardiovascular, HIV, psychiatric and related diseases, and epilepsy.

On the other hand, the lack of consistency in pharmacogenomics products is one of the major hindrance of the expansion of the market. Nevertheless, the vendors operating in the pharmacogenomics market are expected to gain from increased focus on regenerative medicine and increased awareness of organ transplantation.

Technology-wise, the global pharmacogenomics market can be segmented into sequencing such as sanger sequencing, pyrosequencing, and next-generation sequencing, polymerase chain reaction, and other technologies such as electrophoresis and mass spectrometry. In the current scenario of the market, sequencing dominates the market, particularly since the advent of next generation sequencing, which offers high accuracy, increased throughput screening, and speed. Application-wise, the market can be bifurcated into oncology, pain management, cardiology, and neurological disorders.

Geographically, the report studies the potential of pharmacogenomics market in every major region such as North America, Asia Pacific, Europe, and the Middle East and Africa. Currently, North America is most profitable region, gaining most of the demand from the developed countries of the U.S. and Canada. However, Asia Pacific is also expected to increment the demand steadily during the forecast period due to improving healthcare facilities in a number of emerging economies.

Some of the most prominent players operating in the global pharmacogenomics market are GE Healthcare, GlaxoSmithKline, GeneDX, Pfizer, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Abbott Laboratories, Inc., Assurex Health, Affymetrix, Inc., Bayer AG, Illumina, Inc., Merck & Co, Myriad Genetics, Inc., Johnson & Johnson, Pathway Genomics, Teva Pharmaceutical Industries Ltd, Qiagen, Inc., and Thermo Fisher Scientific.

Download a PDF Brochure ofPharmacogenomics Market Research Report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3615

Go here to read the rest:
Pharmacogenomics Market: Improving Healthcare Infrastructure in APAC Incrementing Demand - Edition Truth

ACE Inhibitors Benazepril (Lotensin) ACE Captopril (Capoten) ACE AGTR1 Perindopril (Aceon) ACE AGTR1 Quinapril (Accupril) ACE Angiotensin II Receptor Blockers Candesartan (Atacand) AGTR1 Irbesartan (Avapro) ACE Losartan (Cozaar) ABCB1 AGTR1 Antianginal Agent Ranolazine (Ranexa) CYP2D6 Antiarrhythmic Agent Amiodarone (Cordarone) CYP3A4 NOS1AP Digoxin (Lanoxin) ABCB1 Dronedarone (Multaq) CYP3A4 Flecainide (Tambocor) CYP2D6 Propafenone (Rythmol) CYP2D6 Anticoagulants Phenprocoumon (Marcoumar) CYP4F2 Rivaroxaban (Xarelto) CYP3A4 Warfarin (Coumadin) CYP2C9 VKORC1 Antiplatelets Clopidogrel (Plavix) CYP2C19 Ticagrelor (Brilinta) CYP3A4 Beta Blockers Atenolol (Tenormin) ADRA2A Carvedilol (Coreg) CYP2D6 Nebivolol (Bystolic) CYP2D6 Propranolol (Inderal LA) CYP2D6 Metoprolol Tartrate (Lopressor) CYP2D6 Calcium Channel Blockers Amiodarone (Cordarone) NOS1AP Amlodipine (Norvasc) CYP3A4 NOS1AP Diltiazem (Cardizem) CYP3A4 Felodipine (Plendil) CYP3A4 Lercanidipine (Zanidip) CYP3A4 Nifedipine (Adalat) NOS1AP Nisoldipine (Sular) CYP3A4 Nitrendipine (Nitrepin) AGTR1 CYP3A4 Verapamil (Calan) NOS1AP Diuretics Bumetanide (Bumex) ACE Furosemide (Lasix) ACE Hydrochlorothiazide (Microzide) ACE AGTR1 Spironolactone/HCTZ (Aldactazide) ADTR1 ACE Spironolactone (Aldactone) ACE Torasemide (Demadex) ACE Phosphodiesterase Inhibitors Cilostazol (Pletal) CYP3A4 Antilipemic Agent Atorvastatin (Lipitor) ABCB1 APOE CYP3A4 CYP3A5 KIF6 SLCO1B1 Fluvastatin (Lescol) ACE Lovastatin (Mevacor) CYP3A4 CYP3A5 Pitavastatin (Livalo) SLCO1B1 Pravastatin (Pravachol) KIF6 SLCO1B1 Rosuvastatin (Crestor) SLCO1B1 Simvastatin (Zocor) ABCB1 CYP3A4 CYP3A5 SLCO1B1 Atorvastatin/Ezetimibe (Liptruzet) ABCB1 APOE CYP3A4 KIF6 SLOC1B1 Fenofibrate (Tricor) APOE Simvastatin/Ezetimibe (Vytorin) ABCB1 SLCO1B1 Vasodilators Nitroprusside (Nipride) ACE Hydralazine NAT2 Hydralazine/Isosorbide (Bidil) NAT2 Miscellaneous Cardiovascular Agents Ivabradine (Corlanor) CYP3A4 ACE Inhibitors/Diuretics Quinapril/HCTZ (Accuretic) ACE AGTR1 Captopril/HCTZ (Capozide) ACE AGTR1 Benazepril/HCTZ (Lotensin HCT) ACE AGTR1 Lisinopril/HCTZ (Prinzide) AGTR1 Enalapril/HCTZ (Vaseretic) AGTR1 ARBs/Diuretics Candesartan/HCTZ (Atacand HCT) AGTR1 Irbesartan/HCTZ (Avalide) ACE AGTR1 Losartan/HCTZ (Hyzaar) AGTR1 ABCB1 Beta-Blocker/Diuretic Metoprolol/HCTZ (Lopressor HCT) CYP2D6 AGTR1 CCB/ACE Inhibitor Amlodipine/Benazepril (Lotrel) ACE CYP3A4 NO1SAP

Go here to read the rest:
PGxOne Pharmacogenomics Test | Admera Health

PARSIPPANY, NJ, April 22, 2020 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at5:00 pm today, Wednesday April 22, 2020 at 5:00 p.m. Eastern time.

The conference call can be accessed as follows:

Date and Time:Wednesday, April 22, 2020 at 5:00 p.m. ETDial-in Number (Domestic):+1 (877) 407-9716Dial-in Number (International):+1 (201) 493-6779Confirmation Number:137025801Webcast Access: http://public.viavid.com/index.php?id=139473

Following the conclusion of the conference call, a replay will be available through May 6, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Companys website at http://www.interpacediagnostics.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Companys website for 90 days.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through the Interpace Diagnostics division, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through the Pharma Solutions Division, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goal of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website atwww.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement, including the potential adverse impact of the Coronavirus (COVID-19) pandemic, our history of operating losses and the limited revenue generated by our clinical and pharma solutions customers, Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K filed on April 22, 2020. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:Investor RelationsEdison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

Continued here:
Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial...

VANCOUVER, British Columbia, March 13, 2020 (GLOBE NEWSWIRE) -- For people with mental health conditions, finding a medication that works without causing severe side effects is often a matter of trial-and-error. This can contribute to a lower adherence to treatment regimens and poorer health, as well as increased costs to the health care system.

Pharmacogenomics can improve a persons health by helping them know ahead of time whether a drug is likely to be an effective treatment and be safe for them to take without triggering an adverse reaction. This is one of the strongest examples to show how precision health holds real potential to end the trial-and-error approach to therapy.

However, there are still many questions to be answered before there can be wider adoption of pharmacogenomic testing in a clinical setting. In a new $1.5 million project, supported by funding from Genome BC, Genome Canada and the Michael Smith Foundation for Health Research, University of British Columbia researchers, Dr. Stirling Bryan and Dr. Jehannine Austin, are investigating if pharmacogenomic testing should be routinely used in BC for people with depression.

Our goal is to gather the necessary information to assess the improvement in patient health, as well as whether the testing is good value for money for the health system, said Dr. Jehannine Austin. The multidisciplinary team we have assembled includes people with diverse backgrounds and skills, including patient partners with lived experiences.

The work will involve reviewing existing studies to learn from the research of others and collecting BC specific information from the records kept by the health care system. The team will also apply extensive stakeholder engagement, talking to patients, doctors, nurses, pharmacists, counsellors, and others providing care for patients with mental health conditions in BC.

We want to gain insight into the typical experiences of patients, said Dr. Stirling Bryan. This information will be used in a simulation model, where we can count the health benefits to patients and the costs of changing practice to include routine use of pharmacogenomics testing for depression.

Pharmacogenomics shows significant potential for delivering precision health care, said Dr. Ellie Griffith, Sector Director, Health at Genome BC. If the findings indicate that pharmacogenomics testing provides value to both patients and the health care system, this information could be used to bring a positive change to how we care for patients with depression in BC.

MSFHR is committed to partnering on strategic initiatives enabling BC researchers to generate and apply much needed research evidence in areas of high priority to our provinces health system, says Dr. Bev Holmes, President and CEO, Michael Smith Foundation for Health Research.

Genome British Columbia leads genomics innovation on Canadas West Coast and facilitates the integration of genomics into society. A recognized catalyst for government and industry, Genome BC invests in research, entrepreneurship and commercialization in life sciences to address challenges in key sectors such as health, forestry, fisheries and aquaculture, agrifood, energy, mining and environment. Genome BC partners with many national and international public and private funding organizations to drive BCs bioeconomy. http://www.genomebc.ca

Michael Smith Foundation for Health Research (MSFHR), funded by the Province of British Columbia, is BC's health research funding agency. MSFHR helps develop, retain and recruit the talented people whose research improves the health of British Columbians, addresses health system priorities, creates jobs and adds to the knowledge economy. Learn more at http://www.msfhr.org.

Genome Canada is a not-for-profit organization that acts as a catalyst for developing and applying genomics and genomic-based technologies, to create economic and social benefits for Canadians. Genome Canada connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation, and translates discoveries into applications and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries & aquaculture, energy, mining, and the environment. http://www.genomecanada.ca

Story continues

Go here to read the rest:
BC researchers are exploring the use of genomics to improve drug treatments for people with depression - Yahoo Finance

DUBLIN, Feb. 20, 2020 /PRNewswire/ -- The "Global Personalized Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026, growing at a CAGR of 12.1% during the forecast period.

The efficient and advanced technology and higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

Based on the End-user, the hospital's segment is estimated to have a lucrative growth due to the lower cost personalized medicines availability in the hospitals. As the practice of personalized medicine becomes more widespread, hospitals will also experience the need to adapt. That does not mean every hospital and medical centre should try and drive the science, but they should be open to collaborations to facilitate such work.

The key vendors mentioned are Abbott Laboratories, Affymetrix Incorporated, Agendia N.V, Agilent Technologies, Inc, Amgen, Inc, Asuragen Incorporated, Bayer Healthcare Pharmaceuticals, Llc, Celera Diagnostics LLC, Celgene Corporation, Roche Diagnostics Corporation, Precision Biologics Incorporated, Siemens Healthcare Diagnostics, Inc, Sigma-Aldrich Corporation, Johnson & Johnson, Novartis AG, Decode Genetics Inc., Exact Science Corporation, Exagen Diagnostics Inc., GE Healthcare, and Genelex Corporation.

Key Questions Answered in the Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics3.1 Drivers3.2 Restraints

4 Market Environment

5 Global Personalized Medicine Market, By Product5.1 Introduction5.2 Diagnostics5.3 Personalized Medical Care5.4 Personalized Nutrition & Wellness5.5 Therapeutics

6 Global Personalized Medicine Market, By Technology6.1 Introduction6.2 Metabolomics6.3 Pharmacodynamics6.4 Pharmacogenetics6.5 Pharmacogenomics6.6 Pharmacokinetics6.7 Pharmacoproteomics6.8 Point-of-Care Testing6.9 Stem Cell Therapy

7 Global Personalized Medicine Market, By Therapeutic Area7.1 Introduction7.2 Autoimmune Diseases7.3 Blood Transfusion Safety7.4 Cancer Management7.5 Cardiovascular Diseases (CVD)7.6 Central Nervous System (CNS) Disorders7.7 Coagulation Therapy7.8 Diabetes7.9 Infectious Diseases7.10 Antiviral7.11 Neurology7.12 Psychiatry7.13 Oncology7.14 Immunology7.15 Respiratory

8 Global Personalized Medicine Market, By Distribution Channel8.1 Introduction8.2 Dietary Care Centers8.3 Hospital's Pharmacies8.4 Retail Pharmacies8.5 Other Distribution Channels

9 Global Personalized Medicine Market, By Application9.1 Introduction9.2 Biomarker Identification9.3 Clinical Research Applications9.4 Companion Diagnostics9.5 Health Informatics

10 Global Personalized Medicine Market, By End-user10.1 Introduction10.2 Academic Institutes10.3 Bio and Health Informatics Companies10.4 Clinical Care and Research Laboratories10.5 Contract Research Organizations10.6 Hospitals10.7 Molecular Diagnostic Laboratories and Testing Facilities10.8 Research Laboratories10.9 Service Providers10.10 Partner10.11 Venture Capitalists10.12 Other End-users

11 Global Personalized Medicine Market, By Geography11.1 North America11.2 Europe11.3 Asia-Pacific11.4 South America11.5 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape13.1 Abbott Laboratories13.2 Affymetrix Incorporated13.3 Agendia N.V13.4 Agilent Technologies Inc.13.5 Amgen Inc.13.6 Asuragen Incorporated13.7 Bayer Healthcare Pharmaceuticals, LLC13.8 Celera Diagnostics LLC13.9 Celgene Corporation13.10 Roche Diagnostics Corporation13.11 Precision Biologics Incorporated13.12 Siemens Healthcare Diagnostics Inc.13.13 Sigma-Aldrich Corporation13.14 Johnson & Johnson13.15 Novartis AG13.16 Decode Genetics Inc.13.17 Exact Science Corporation13.18 Exagen Diagnostics Inc.13.19 GE Healthcare13.20 Genelex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/37rw80

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-worth-3-92-trillion-by-2026---insights-into-diagnostics-medical-care-nutrition--wellness-and-therapeutics-301008591.html

SOURCE Research and Markets

View original post here:
Personalized Medicine Market Worth $3.92 Trillion by 2026 - Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics - P&T...

Feb. 19, 2020 13:00 UTC

Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantOmics, LLC, the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed study in Breast Cancer Research, a Springer Nature journal, on a novel AI technique in breast cancer. The study reports on a novel deep-learning system of digital pathology images and omics data used together to more precisely identify mechanisms of therapy resistance.

NantOmics scientists trained a deep-neural network on diagnostic slide images from 443 breast tumors that had previously undergone PAM50 subtyping to classify patches of the tumor images into four major molecular subtypes of breast cancer (basal-like, HER2-enriched, luminal A, and luminal B). The algorithm was then validated and demonstrated the capability to establish accurate breast cancer sub-typing in 222 samples from a retained set of tumors. By focusing the neural-networks attention on cancer-rich regions in the diagnostic images, this deep-learning algorithm identifies patient biopsies that are a mixture of different molecular subtypes, a classification that is less definable from molecular pathology techniques. Patients with heterogeneous biopsies such as mixtures of basal-like and luminal disease have a different survival profile than patients with homogeneous disease, and may potentially benefit from a more tailored therapy regimen.

Breast cancer can be subtyped into at least five distinct disease-types with very different prognoses and responses to therapy. These subtypes are characterized as clinically important, yet are typically only achievable by RNA expression profiling, Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth explained. With this AI technique we achieved 87 percent accuracy rate in detecting which patients had basal-like breast cancer (i.e., triple negative breast cancer), one of the most aggressive subtypes, he said.

Our analysis builds on our breadth of advanced machine learning technologies to better support providers in therapeutic decision-making and to improve the capabilities of the underlying molecular analysis technology platforms that we use at NantHealth and NantOmics, said Soon-Shiong. Through the advances of machine vision and augmented intelligence, we have developed a rapid and cost-effective deep-learning technique to unlock the rich information in readily-available diagnostic slide images to define subtypes concordant with their underlying molecular designations.

Breast Cancer Research, a Springer Nature journal, is an international, peer-reviewed online journal publishing original research, reviews, editorials and reports in breast cancer. Breast Cancer Research is published by BMC, an open access publisher that produces over 250 scientific journals and according to its website, is the highest ranked breast cancer focused title in the field.

About NantOmics NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic and machine learning AI capabilities to provide actionable intelligence and molecularly driven decision support for patients and their providers. NantOmics is the first molecular in vitro diagnostics company to accurately identify mutations and true tumor mutation burden (TMB) from proprietary tumor-normal sequencing. The identified mutations and correlative calculation of true TMB, combined with proprietary expression analysis of immuno-oncology biomarkers and novel deep-learning derived digital pathology solutions, establish the framework for the appropriate use of targeted, chemo- and immunotherapies. NantOmics computational analysis engine, an organically grown, scalable, cloud-based infrastructure capable of processing and storing thousands of genomes per day, uses novel AI tools to combine expression analysis with near real-time genomic variance computing to generate precise N of 1 neoepitope vaccine therapies for cancer patients. For more information please visit http://www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantHealth NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

Forward-Looking Statements: NantHealth This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words expects, anticipates, believes, intends, estimates, plans, will, outlook and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005341/en/

Link:
NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of...

Guilherme S Lopes,1,2 Suzette J Bielinski,2 Ann M Moyer,3 John Logan Black III,3 Debra J Jacobson,1 Ruoxiang Jiang,1 Nicholas B Larson,1 Jennifer L St Sauver2

1Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 2Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 3Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Correspondence: Guilherme S LopesDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USATel +1 507 422 6094Email lopes.guilherme@mayo.edu

Background: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control and adverse reactions related to codeine and tramadol use. We conducted additional analyses to determine whether our results were consistent among men and women.Methods: We used data from 2,877 participants in the RIGHT Protocol who were prescribed codeine and/or tramadol between 01/01/2005 and 12/31/2017 and who were not prescribed CYP2D6 inhibitors within 1 year prior to the opioid prescription. CYP2D6 phenotype categories were condensed into four groups: (1) Ultra-rapid and Rapid (n = 61), (2) Normal and Intermediate to Normal (n = 1,448), (3) Intermediate and Intermediate to Poor (n = 1,175), and (4) Poor metabolizer status (n = 193). Opioid-related outcomes included indications of poor pain control or adverse reactions related to medication use. We modeled the risk of each outcome using logistic regression, adjusting for age, sex, race, and ethnicity.Results: The results revealed a trend from poor to ultra-rapid and rapid CYP2D6 phenotypes in which the risk of adverse reactions incrementally increased and the risk of poor pain control incrementally decreased. This trend reached statistical significance among female (but not male) participants. Among normal and intermediate to normal metabolizers, a larger proportion of women experienced adverse reactions relative to men.Discussion: We replicated and extended the findings of previous research indicating associations between CYP2D6 phenotypes and response to opioids. In addition, the observed associations were stronger in women than in men. We recommend sex differences to be factored in future research investigating associations between pharmacogenomics and response to medications.

Keywords: opioids, codeine, tramadol, pharmacogenomics, sex differences, CYP2D6

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continue reading here:
Sex Differences in Associations Between CYP2D6 Phenotypes and Response | PGPM - Dove Medical Press

NEW YORK, Dec. 26, 2019 /PRNewswire/ --

Global Modular Laboratory Automation Market: About this market This modular laboratory automation market analysis considers sales from hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, and other end-users. Our study also finds the sales of modular laboratory automation in Asia, Europe, North America, and ROW. In 2019, the hospitals and diagnostic laboratories segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing prevalence of chronic and infectious diseases such as cancer, diabetes, influenza, and cardiovascular will play a significant role in the hospitals and diagnostic laboratories segment to maintain its market position. Also, our global modular laboratory automation market report looks at factors such as increasing workload in clinical and diagnostic laboratories, and demand for automation among reference laboratories. However, implementation and integration of automated systems into existing laboratory space, requirement for high capital investments, and risk of prolonged downtime due to automation failure may hamper the growth of the modular laboratory automation industry over the forecast period.

Read the full report: https://www.reportlinker.com/p05834273/?utm_source=PRN

Global Modular Laboratory Automation Market: Overview Rising drug development and research activities The drug R&D sector is witnessing rapid growth with the increase in drug discovery activities and approvals. Drug discovery activities involve safety testing procedures such as validation testing, pharmacogenomic testing, and toxicity testing. This is encouraging drug development researchers to use automation technologies, which are used in safety testing procedures to automate the preanalytical and post-analytical processing. It enhances the process by developing a streamlined workflow and minimizing manual intervention. Thus, the rise in drug development and research activities will lead to the expansion of the global modular laboratory automation market at a CAGR of over 6% during the forecast period. Integration of AI and analytical tools in laboratory workflow Vendors are finding automation and Al as complementing technologies that are together ensuring the optimum utilization of laboratory resources and helping in increasing productivity. The integration of Al and analytical tools has resulted in the introduction of smart modular laboratory automation solutions, which have allowed easy, reliable, and secured networking of automated modules at the field level. Additionally, features such as intelligent control and real-time update about the economic consumption of water and raw materials help provide significant cost benefits to the laboratories deploying such smart systems. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape With the presence of a few major players, the global modular laboratory automation market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading modular laboratory automation manufacturers, that include Agilent Technologies Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., QIAGEN NV, Shimadzu Corp., Siemens AG, and Thermo Fisher Scientific Inc. Also, the modular laboratory automation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Read the full report: https://www.reportlinker.com/p05834273/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-modular-laboratory-automation-market-at-a-cagr-of-over-6-during-the-forecast-period-300979382.html

SOURCE Reportlinker

Read more from the original source:
The global modular laboratory automation market at a CAGR of over 6% during the forecast period - P&T Community

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium

NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO).

The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology education, doctors and care teams.

NantHealths presentation utilized data on whole exome (WES) DNA tumor and paired germline and matched deep whole transcriptomic sequencing (RNA-Seq) to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH). ERBB2 (HER2) gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification (consensus molecular subtype in CRC). This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.

"Our analysis shows that conventional testing methods may miss potentially actionable HER2 signaling in CRC patients," said Sandeep "Bobby" Reddy, MD, Chief Medical Officer, NantHealth. "The significant difference suggests that up to 40% more patients may be eligible for HER2 directed therapies, which has implications for drug development and clinical trials."

Title: "Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients"

Authors: Sandeep K. Reddy, M.D., Tara Elisabeth Seery, M.D., Christopher W. Szeto, Ph.D.

Poster Session and Number: Poster session C (Board #A14)

Location: Moscone West Building

Date and Time: January 25, 2020, 6:30-7:55 AM PT and 12:15-1:45 PM PT

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

About NantOmics:

NantOmics, a member of the NantWorks ecosystem of companies, invented and developed the technologies that drive NantHealths GPS Cancer platform. GPS Cancer provides actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing molecular variances and profiles that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances from DNA to RNA to protein to drug. Having pioneered tumor-normal DNA sequencing and introduced whole RNA transcriptomic analysis to better inform clinical treatment decisions, NantOmics has provided molecular insights for thousands of cancer patients.

NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time and correlating proteomic pathway analysis with quantitative gene expression and pharmacogenomic signatures, which guides the use of immunotherapies, chemotherapies and targeted therapies. Clinical studies for neoepitope vaccines using NantOmics proprietary technologies and novel artificial intelligence platforms are currently underway. For more information please visit http://www.nantomics.com.

Story continues

Forward-Looking Statements: NantHealth

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200125005009/en/

Contacts

NANT Jen HodsonJen@nant.com 562-397-3639

Read more here:
Data from NantHealths GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients - Yahoo Finance

DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Red Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

This study on the red biotechnology market provides readers with a holistic market overview, through an extensive analysis of the market.

The report analyzes the market with regards to the historical and current data to provide a forecast for the period of 2019-2027. Actionable insights and findings pertaining to the red biotechnology market help report readers take major business decisions that support their long-term business growth.

The study includes the compilation of the assessment of significant market dynamics such as key industry trends and major developments carried out by leading players, along with a detailed competitive assessment. The study is divided into key sections to provide readers with an individual understanding of the various aspects of the red biotechnology market.

Key Questions Answered

Key Topics Covered

1. Global Red Biotechnology Market - Preface1.1. Market Definition and Scope1.2. Market Segmentation1.3. Key Research Objectives1.4. Research Highlights

2. Assumptions and Research Methodology2.1. Red Biotechnology Market Definition2.2. Red Biotechnology Market Taxonomy

3. Executive Summary : Global Red Biotechnology Market3.1. Introduction3.1.1. Definition3.1.2. Industry Evolution/Developments3.2. Overview3.3. Market Dynamics3.3.1. Drivers3.3.2. Restrains3.3.3. Opportunities3.4. Global Red Biotechnology Market Analysis and Forecast, 2017-20273.5. Market Revenue Projections (US$ Bn)4. Market Outlook4.1. Pipeline Analysis4.2. Mergers & Acquisitions

5. Global Red Biotechnology Market Analysis and Forecast, by Application 5.1. Introduction5.2. Key Findings/Developments, by Type 5.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2017-20275.3.1. Biopharmaceutical Production5.3.2. Gene Therapy5.3.3. Pharmacogenomics5.3.4. Genetic Testing5.4. Global Red Biotechnology Market Attractiveness Analysis, by Application

6. Global Red Biotechnology Market Analysis and Forecast, by End-user 6.1. Introduction6.2. Key Findings/Developments, by End-user 6.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2017-20276.3.1. Pharmaceutical Industry 6.3.2. CMO & CRO6.3.3. Research Institutes6.3.4. Others 6.4. Global Red Biotechnology Market Attractiveness Analysis, by End-user

7. Global Red Biotechnology Market Analysis and Forecast, by Region/sub-Region7.1. Key Findings/Developments 7.2. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Region/Sub-Region, 2017-20277.2.1. North America7.2.2. Europe7.2.3. Asia-Pacific 7.2.4. Latin America7.2.5. Middle East & Africa (MEA)7.3. Global Red Biotechnology Market Attractiveness Analysis, by Region/Sub-Region

8. North America Red Biotechnology Market Analysis and Forecast

9. Europe Red Biotechnology Market Analysis and Forecast

10. Asia-Pacific Red Biotechnology Market Analysis and Forecast

11. Latin America Red Biotechnology Market Analysis and Forecast

12. Middle East & Africa Red Biotechnology Market Analysis and Forecast

13. Competition Landscape13.1. Market Player - Competition Matrix 13.2. Market Share Analysis, by Company (2018)13.3. Company Profiles13.3.1. Pfizer Inc.13.3.2. Biogen Inc.13.3.3. Amgen Inc.13.3.4. AstraZeneca PLC13.3.5. Gilead Sciences Inc.13.3.6. Celgene Corporation13.3.7. F. Hoffmann-La Roche Ltd.13.3.8. Merck KGaA13.3.9. Regeneron Pharmaceuticals Inc.13.3.10. Takeda Pharmaceutical Company Limited

For more information about this report visit https://www.researchandmarkets.com/r/xf6hwp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more here:
Insights Into the World's Red Biotechnology Market, 2017-2019 & 2027 - Emerging Opportunities, Revenue Projections, Leading Players - PRNewswire

PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Companys financial results and provide a general business update.

All listeners should confirm they are dialing in for the Interpace conference call with the operator who will promptly place them into the call. A webcast replay will be available on the companys website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the companys website for 90 days.

About Interpace, Inc.

Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpaces Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDXthat differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpaces Biopharma Business is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpaces website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Story continues

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

Visit link:
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 - Yahoo Finance